The "four types of peptides" most people search for is a skincare-industry classification: signal peptides, carrier peptides, enzyme-inhibitor peptides, and neurotransmitter-inhibitor peptides. It is a real framework from the cosmetic literature — but it only covers topical peptides. Biology as a whole has no official four-type list; scientists group peptides by function instead (hormonal, signalling, antimicrobial, structural).
The four types (as the skincare industry defines them)
When articles list exactly four types of peptides, they are almost always drawing on the classification used in cosmetic dermatology. A peer-reviewed review of topical anti-aging peptides in the International Journal of Cosmetic Science categorized them into precisely these four groups: signal peptides, enzyme-inhibitor peptides, neurotransmitter-inhibitor peptides, and carrier peptides (Gorouhi & Maibach, 2009).
- Signal peptides — short fragments intended to signal skin cells to produce more collagen or extracellular-matrix components.
- Carrier peptides — peptides that deliver trace elements to the skin; the classic example is the copper-binding peptide GHK-Cu.
- Enzyme-inhibitor peptides — fragments meant to slow enzymes that break down collagen and other skin proteins.
- Neurotransmitter-inhibitor peptides — topical peptides marketed as milder alternatives to botulinum toxin, aiming to reduce muscle-contraction wrinkles.
Two honest caveats: this taxonomy describes intended cosmetic mechanisms, not proven clinical outcomes — the same review was written to assess how thin the controlled-trial evidence is — and it says nothing about injectable, hormonal, or metabolic peptides, which is where most peptide science actually happens.
How scientists actually group peptides
Outside marketing copy, there is no canonical four-bucket scheme. Researchers group peptides by what they do:
- Hormonal peptides — chemical messengers released into circulation: insulin, GLP-1, oxytocin, parathyroid hormone fragments. This group contains nearly all approved peptide medicines, including semaglutide and tirzepatide.
- Signalling peptides — local messengers acting on nearby cells and tissues rather than body-wide, such as growth-factor fragments involved in repair and inflammation.
- Antimicrobial peptides — an ancient arm of immune defense found across multicellular life, with broad activity against bacteria, fungi, viruses, and protozoa (Zasloff, Nature 2002).
- Structural peptides — fragments of structural proteins such as collagen and elastin, relevant to skin, bone, and connective tissue (and to the collagen-peptide supplement market).
These functional families are how the therapeutic-peptide literature is organized: a 2022 review in Signal Transduction and Targeted Therapy surveys approved and investigational peptides across metabolic, cardiovascular, and other organ systems by the receptor pathways they act on, not by a four-type list (Wang et al., 2022).
How this catalog groups peptides
For practical navigation, this site organizes peptides the way people encounter them — by therapeutic context rather than biochemical family:
- Metabolic peptides — GLP-1 and related incretin drugs discussed for diabetes and weight management.
- Healing and recovery peptides — experimental compounds such as BPC-157 and TB-500, supported mainly by preclinical data.
- Cosmetic and skin peptides — topical and injectable compounds from the skincare taxonomy above.
- Performance-related peptides — growth-hormone secretagogues and similar compounds, many of which are prohibited in sport.
Any such grouping is a filing system, not a scientific claim: it tells you what a peptide is used or marketed for, which is a different question from what the evidence shows it does.
Limits of simple labels
Whichever scheme you use, the boundaries leak. GHK-Cu is a "carrier peptide" in the cosmetic taxonomy but also behaves as a signalling fragment in wound-healing models. GLP-1 is a hormone, a satiety signal, and the scaffold for an entire drug class at once. And two peptides in the same bucket can sit at opposite ends of the evidence spectrum — one an approved medicine with large randomized trials, the other a research compound with only animal data.
The type label is a starting point. The questions that matter for any individual peptide are the same regardless of category: what receptor or target does it act on, what human evidence exists, and what is its regulatory status.